O
APTO

OrbiMed’s Aptose Biosciences, Inc. APTO Stock Holding History

OrbiMed’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,765
Closed -$5.66M – 181
2021
Q3 		$5.66M Sell
5,765
-12,079
-68% -$15.1M 0.06% 151
2021
Q2 		$26.7M Hold
17,844
– – 0.27% 87
2021
Q1 		$48M Hold
17,844
– – 0.45% 62
2020
Q4 		$35.2M Buy
17,844
+15,849
+794% +$37.2M 0.31% 76
2020
Q3 		$5.38M Sell
1,995
-118
-6% -$294K 0.07% 125
2020
Q2 		$6M Buy
2,113
+649
+44% +$2.09M 0.08% 113
2020
Q1 		$3.91M Sell
1,464
-1,092
-43% -$3.26M 0.07% 112
2019
Q4 		$6.52M Buy
+2,556
New +$3.33M 0.09% 93

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

OrbiMed's APTO Position: Q4 2021 in Review

OrbiMed sold out of Aptose Biosciences, Inc. (APTO) in Q4 2021, closing a stake of 5,765 shares — an estimated $5.66M sold.

OrbiMed first reported a position in APTO in Q4 2019 and held it in 8 quarters. The position peaked at $48M in Q1 2021. 58 funds tracked by Wall St. Rank hold APTO as of Q4 2021.

  • OrbiMed reported no remaining Aptose Biosciences, Inc. position as of Q4 2021 after selling out during the quarter.
  • OrbiMed sold 5,765 Aptose Biosciences, Inc. shares in Q4 2021, an estimated $5.66M.
  • OrbiMed first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 8 quarters.
  • OrbiMed's Aptose Biosciences, Inc. position peaked at $48M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.